LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

Home・Lista de Ações・CytoSorbents Corp

CytoSorbents Corp

Fechado

SetorSaúde

0.44 -4.35

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

0.44

Máximo

0.46

Indicadores-chave
By Trading Economics
Rendimento	368K -5.1M
Vendas	-370K 8.9M
EPS	-0.08
Margem de lucro	-57.863
Funcionários	129
EBITDA	648K -3M

Recomendações
By TipRanks
Recomendações	Neutro
Previsão para 12 meses	+59.57% upside

Dividendos
By Dow Jones
Próximos Ganhos	6 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-9.5M 30M
Abertura anterior	4.79
Fecho anterior	0.44

Sentimento de Notícias

By Acuity

46%

54%

157 / 345 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

0.705 / 0.771 Suporte e Resistência

CytoSorbents Corp Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

19 de mai. de 2026, 20:36 UTC

Aquisições, Fusões, Aquisições de Empresas

Analog Devices to Buy Empower Semiconductor for $1.5 Billion

19 de mai. de 2026, 23:47 UTC

Conversa de Mercado

Nikkei May Decline as Concerns About Energy, Material Costs Persists -- Market Talk

19 de mai. de 2026, 23:34 UTC

Conversa de Mercado

Gold Edges Higher on Possible Technical Recovery -- Market Talk

19 de mai. de 2026, 23:28 UTC

Conversa de Mercado

Ganhos

Global Forex and Fixed Income Roundup: Market Talk

19 de mai. de 2026, 23:28 UTC

Conversa de Mercado

Ganhos

F&P Healthcare's Outlook Key for Investors -- Market Talk

19 de mai. de 2026, 23:10 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

19 de mai. de 2026, 23:10 UTC

Conversa de Mercado

Kiwi Property's Dividend Growth Reliant on Several Factors -- Market Talk

19 de mai. de 2026, 22:02 UTC

Ganhos

ZTO Express (Cayman): Di Xu to Resign From Board

19 de mai. de 2026, 22:01 UTC

Ganhos

ZTO Express (Cayman) 1Q Adj EPS 43c >ZTO

19 de mai. de 2026, 22:01 UTC

Ganhos

ZTO Express (Cayman) 1Q EPS 39c >ZTO

19 de mai. de 2026, 22:00 UTC

Ganhos

ZTO Express (Cayman) 1Q Rev $1.93B >ZTO

19 de mai. de 2026, 21:37 UTC

Ganhos

Cracks Are Starting to Appear in the Chip Stock Rally -- Barrons.com

19 de mai. de 2026, 21:31 UTC

Aquisições, Fusões, Aquisições de Empresas

How NextEra Can Fix Dominion's Strange AI Problem -- Barrons.com

19 de mai. de 2026, 21:01 UTC

Ganhos

Home Depot Beats Earnings Estimates as Shoppers Defy Inflation Fears. The Stock Advances. -- Barrons.com

19 de mai. de 2026, 20:58 UTC

Ganhos

These Stocks Are Today's Movers: CoreWeave, Nvidia, Home Depot, Akamai, Agilysys, Micron, and More -- Barrons.com

19 de mai. de 2026, 20:46 UTC

Ações em Alta

Stocks to Watch Recap: ServiceNow, Home Depot, CoreWeave -- WSJ

19 de mai. de 2026, 20:43 UTC

Conversa de Mercado

Canada 30-Year Yield Hits Highest Level Since 2010 -- Market Talk

19 de mai. de 2026, 20:34 UTC

Ganhos

James Hardie Industries Sees FY27 Sales $5.25B-$5.41B >JHX

19 de mai. de 2026, 20:32 UTC

Ganhos

James Hardie Industries: Targeting Pro Forma Adjusted EBITDA Growth of 4% to 8% in FY27 >JHX

19 de mai. de 2026, 20:32 UTC

Ganhos

James Hardie Industries 4Q EPS 5c >JHX

19 de mai. de 2026, 20:32 UTC

Ganhos

James Hardie Industries 4Q Sales $1.4B >JHX

19 de mai. de 2026, 20:21 UTC

Aquisições, Fusões, Aquisições de Empresas

Analog Devices to Buy Empower Semiconductor for $1.5B

19 de mai. de 2026, 20:18 UTC

Conversa de Mercado

Canada CPI Data Has Accounting Quirk Related to Travel Tours -- Market Talk

19 de mai. de 2026, 20:13 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

19 de mai. de 2026, 20:13 UTC

Conversa de Mercado

'Hard to Square' Canada Rate Hikes Expectations Given Mild Core -- Market Talk

19 de mai. de 2026, 20:03 UTC

Aquisições, Fusões, Aquisições de Empresas

Analog Devices: Deal Further Advances Position as Strategic, System-Level Grid-To-Core Power Partner for Hyperscalers, AI Silicon Developers >ADI

19 de mai. de 2026, 20:03 UTC

Aquisições, Fusões, Aquisições de Empresas

Analog Devices: Phillips Will Continue Leading IVR Technology Efforts as Part of ADI >ADI

19 de mai. de 2026, 20:02 UTC

Aquisições, Fusões, Aquisições de Empresas

Analog Devices Will Acquire Empower in All-Cash Transaction for $1.5 B >ADI

19 de mai. de 2026, 20:02 UTC

Aquisições, Fusões, Aquisições de Empresas

Analog Devices to Acquire Empower Semiconductor, Expanding Its Next-Generation High-Density Power Portfolio for the AI Era

19 de mai. de 2026, 19:23 UTC

Conversa de Mercado

Oil Futures Slip With Market Back on U.S.-Iran Deal Watch -- Market Talk

Comparação entre Pares

Variação de preço

CytoSorbents Corp Previsão

Preço-alvo

By TipRanks

59.57% parte superior

Previsão para 12 meses

Média 0.75 USD 59.57%

Máximo 0.75 USD

Mínimo 0.75 USD

Com base em 1 analistas de Wall Street que oferecem metas de preço de 12 meses para CytoSorbents Corp - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

1 ratings

Comprar

Manter

Vender

Com base em 1 analistas que deram avaliações de ações para CytoSorbents Corp - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

0.705 / 0.771Suporte e Resistência

All events are bearish.

Sentimento

By Acuity

157 / 345 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre CytoSorbents Corp

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.